Baidu
map

NATURE:中低收入国家的儿童疫苗和抗生素使用情况

2020-04-30 MedSci原创 MedSci原创

疫苗可以减少抗生素耐药性的负担,部分因为其可以预防感染,而感染的治疗通常包括使用抗生素。然而,至今为止,我们对于疫苗接种对抗生素消耗的影响仍然不甚了解--尤其是在中低收入国家(LMICs)。

疫苗可以减少抗生素耐药性的负担,部分因为其可以预防感染,而感染的治疗通常包括使用抗生素。然而,至今为止,我们对于疫苗接种对抗生素消耗的影响仍然不甚了解--尤其是在中低收入国家(LMICs),那里的抗生素耐药性负担最重。

研究人员发现,最近在世界卫生组织的扩大免疫计划中实施的疫苗可大幅降低5岁以下儿童的抗生素消耗。

通过分析大规模家庭研究的数据,研究人员估计,肺炎球菌共轭疫苗和减毒轮状病毒活疫苗分别对抗生素治疗的急性呼吸道感染和腹泻发病提供了19.7%(95%置信区间,3.4-43.4%)和11.4%(4.0-18.6%)的保护。

在目前的覆盖率下,肺炎球菌和轮状病毒疫苗每年分别预防了 2 380 万和 1 360 万名 5 岁以下儿童的抗生素治疗疾病。

通过实现这些疫苗的全民覆盖目标,可以直接提供保护,预防额外的4 000万例抗生素治疗的疾病。这一证据支持将疫苗列为抗生素耐药性全球战略的优先事项。

 

原始出处:

Joseph A. Lewnard et al. Childhood vaccines and antibiotic use in low- and middle-income countries. NATURE, 2020. 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884296, encodeId=64fa188429621, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 18 03:45:38 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642974, encodeId=2ecd16429e427, content=<a href='/topic/show?id=f746213e822' target=_blank style='color:#2F92EE;'>#中低收入国家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21378, encryptionId=f746213e822, topicName=中低收入国家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35fb23047443, createdName=12499e01m54暂无昵称, createdTime=Thu Jan 28 06:45:38 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954002, encodeId=793a19540028c, content=<a href='/topic/show?id=1c6a262184c' target=_blank style='color:#2F92EE;'>#低收入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26218, encryptionId=1c6a262184c, topicName=低收入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Oct 14 17:45:38 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685167, encodeId=de39168516eb5, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=765028091178, createdName=yangfl15, createdTime=Fri Jan 08 10:45:38 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660841, encodeId=e89d166084153, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Tue Sep 22 09:45:38 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
    2020-12-18 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884296, encodeId=64fa188429621, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 18 03:45:38 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642974, encodeId=2ecd16429e427, content=<a href='/topic/show?id=f746213e822' target=_blank style='color:#2F92EE;'>#中低收入国家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21378, encryptionId=f746213e822, topicName=中低收入国家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35fb23047443, createdName=12499e01m54暂无昵称, createdTime=Thu Jan 28 06:45:38 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954002, encodeId=793a19540028c, content=<a href='/topic/show?id=1c6a262184c' target=_blank style='color:#2F92EE;'>#低收入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26218, encryptionId=1c6a262184c, topicName=低收入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Oct 14 17:45:38 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685167, encodeId=de39168516eb5, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=765028091178, createdName=yangfl15, createdTime=Fri Jan 08 10:45:38 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660841, encodeId=e89d166084153, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Tue Sep 22 09:45:38 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1884296, encodeId=64fa188429621, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 18 03:45:38 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642974, encodeId=2ecd16429e427, content=<a href='/topic/show?id=f746213e822' target=_blank style='color:#2F92EE;'>#中低收入国家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21378, encryptionId=f746213e822, topicName=中低收入国家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35fb23047443, createdName=12499e01m54暂无昵称, createdTime=Thu Jan 28 06:45:38 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954002, encodeId=793a19540028c, content=<a href='/topic/show?id=1c6a262184c' target=_blank style='color:#2F92EE;'>#低收入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26218, encryptionId=1c6a262184c, topicName=低收入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Oct 14 17:45:38 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685167, encodeId=de39168516eb5, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=765028091178, createdName=yangfl15, createdTime=Fri Jan 08 10:45:38 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660841, encodeId=e89d166084153, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Tue Sep 22 09:45:38 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1884296, encodeId=64fa188429621, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 18 03:45:38 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642974, encodeId=2ecd16429e427, content=<a href='/topic/show?id=f746213e822' target=_blank style='color:#2F92EE;'>#中低收入国家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21378, encryptionId=f746213e822, topicName=中低收入国家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35fb23047443, createdName=12499e01m54暂无昵称, createdTime=Thu Jan 28 06:45:38 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954002, encodeId=793a19540028c, content=<a href='/topic/show?id=1c6a262184c' target=_blank style='color:#2F92EE;'>#低收入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26218, encryptionId=1c6a262184c, topicName=低收入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Oct 14 17:45:38 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685167, encodeId=de39168516eb5, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=765028091178, createdName=yangfl15, createdTime=Fri Jan 08 10:45:38 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660841, encodeId=e89d166084153, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Tue Sep 22 09:45:38 CST 2020, time=2020-09-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1884296, encodeId=64fa188429621, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 18 03:45:38 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642974, encodeId=2ecd16429e427, content=<a href='/topic/show?id=f746213e822' target=_blank style='color:#2F92EE;'>#中低收入国家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21378, encryptionId=f746213e822, topicName=中低收入国家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35fb23047443, createdName=12499e01m54暂无昵称, createdTime=Thu Jan 28 06:45:38 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954002, encodeId=793a19540028c, content=<a href='/topic/show?id=1c6a262184c' target=_blank style='color:#2F92EE;'>#低收入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26218, encryptionId=1c6a262184c, topicName=低收入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Oct 14 17:45:38 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685167, encodeId=de39168516eb5, content=<a href='/topic/show?id=9bc05542024' target=_blank style='color:#2F92EE;'>#抗生素使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55420, encryptionId=9bc05542024, topicName=抗生素使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=765028091178, createdName=yangfl15, createdTime=Fri Jan 08 10:45:38 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660841, encodeId=e89d166084153, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Tue Sep 22 09:45:38 CST 2020, time=2020-09-22, status=1, ipAttribution=)]

相关资讯

Nature:新疫苗让疟原虫自我毁灭

4月22日,《自然》发表的一项研究显示,研究人员筛选了对严重疟疾有天然免疫抵抗力的儿童的血液样本,发现了一种针对特殊疟疾蛋白质PfGARP的抗体,这种抗体似乎可以保护儿童免受严重疟疾的侵害。

bioRxiv:一种COVID-19候选疫苗在恒河猴体内试验成功了!

导言:COVID-19在全球的爆发愈演愈烈,全世界都加速了疫苗研制的步伐。现在疫苗可能是治愈新冠病毒的唯一方法,人们迫切希望疫苗能够研发成功,能够尽快投入使用。

姜世勃:广谱抗冠疫苗和药物是战胜新冠疫情的终极武器

在4月23日未来论坛第七期直播中,我们邀请到了复旦大学病原微生物研究所所长姜世勃为我们带来《广谱抗冠疫苗和药物是战胜新冠疫情的终极武器》的主题分享。稿件整理:郭丽洁,中科院生物物理所博士生; 

科普:疫苗是战疫的有效“武器”

今年的世界免疫周是4月24日至30日,主题是“疫苗保护人人”。历史上人类遭遇的天花、脊髓灰质炎等传染病都通过接种疫苗得到了有效控制,在当前的新冠疫情中疫苗更是成为世界的希望。

Nature:新疫苗可使疟原虫自我毁灭

4 月 22 日,《自然》发表的一项研究显示,研究人员筛选了对严重疟疾有天然免疫抵抗力的儿童的血液样本,发现了一种针对特殊疟疾蛋白质 PfGARP 的抗体,这种抗体似乎可以保护儿童免受严重疟疾的侵害。

Valneva和Dynavax宣布开展合作以推进COVID-19的疫苗开发

专注于预防重大疾病的专业疫苗公司Valneva和专注于开发新型疫苗的生物制药公司Dynavax近日宣布,将合作启动COVID-19疫苗的开发。

Baidu
map
Baidu
map
Baidu
map